Aspen pays $1b for Merck API business, 11 products
This article was originally published in Scrip
Johannesburg, South Africa-based Aspen Group will pay $1 billion to acquire an active pharmaceutical ingredient (API) manufacturing business from MSD, known as Merck & Co in the US and Canada, as well as 11 finished products. The deal is meant to bolster Aspen's case in the acquisition of two GlaxoSmithKline blood thinners.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.